MedTrace Logo

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

NCT00221312 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2008-05-08

No results posted yet for this study

Summary

This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition).

During the three to five years prior to the menopause, the rate of bone loss increases. One way that physicians treat this is with oral contraceptive medication. However, the incidence of complications from oral contraceptives after the age of 40 increases. Therefore, a non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a class of compounds called bisphosphonates. This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.

Conditions

  • Perimenopausal Bone Loss

Interventions

DRUG

Fosamax

Sponsors & Collaborators

Principal Investigators

  • Robert B. Jaffe, M.D. · University of California, San Francisco

Eligibility

Min Age
40 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-05-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00221312 on ClinicalTrials.gov